Exscientia
Founded Year
2012Stage
IPO | IPOTotal Raised
$673.7MDate of IPO
10/1/2021Market Cap
0.77BStock Price
6.20Revenue
$0000About Exscientia
Exscientia (NASDAQ: EXAI) is an artificial intelligence (AI)-driven precision medicine company. It develops a variety of therapeutic drugs for diseases such as cancers, inflammatory diseases, blood diseases, and more. The company was founded in 2012 and is based in Oxford, United Kingdom.
Loading...
Loading...
Research containing Exscientia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Exscientia in 6 CB Insights research briefs, most recently on Nov 1, 2023.
Expert Collections containing Exscientia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Exscientia is included in 3 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,958 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Exscientia Patents
Exscientia has filed 3 patents.
The 3 most popular patent topics include:
- acetylcholinesterase inhibitors
- adenosine receptor antagonists
- carbamates
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/4/2019 | 10/17/2023 | Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines | Grant |
Application Date | 6/4/2019 |
|---|---|
Grant Date | 10/17/2023 |
Title | |
Related Topics | Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines |
Status | Grant |
Latest Exscientia News
Nov 21, 2023
News provided by Share this article Fortune editors name the companies leading the way in the AI boom An essential guide to the companies every executive needs to know in the sector attracting one out of every four startup investment dollars Inaugural Fortune 50 AI Innovators includes established players: OpenAI, Anthropic, Google DeepMind, Meta, and Nvidia; and array of emerging players: Adept, Runway, Pinecone, Exscientia, and ARC Representatives of Fortune 50 AI Innovators are attending Fortune's Brainstorm AI conference in San Francisco, Dec 11-12 with founding partner Accenture NEW YORK, Nov. 21, 2023 /PRNewswire/ -- Today Fortune debuted its inaugural Fortune 50 AI Innovators power list, the essential guide to the companies that are creating this future-defining technology, and a sector now attracting one out of every four startup investment dollars. The last few days in the world of AI have proven that readers and investors need to follow the space very closely. "It's a tangled mess out there when it comes to predictions about AI's impact," notes Lee Clifford, Fortune's investing and finance editor. "Will AI create a world where no job is needed? By 2029, will computers have achieved human-level intelligence? Where will the OpenAI drama end up?" Predictions, ideas, and execution around the technology are all over the map, Clifford notes. "But one thing we know for sure about this sector, which is still in its infancy: Investors and companies large and small are taking it seriously," she writes. Fortune notes that Microsoft—itself a major player via its OpenAI investment and partnership—recently found that for every $1 invested in AI, companies are reaping $3.50 in return. And according to Crunchbase, one in four dollars invested in American startups have gone to AI companies this year; already 200 AI unicorns (defined as startups with value more than $1 billion) have been created. But Fortune's editors tamp down the AI hype machine: "As anyone who has lived through a hype cycle about the next huge thing knows, even the hottest sector mints far more miserable failures than stunning successes." For the inaugural Fortune 50 AI Innovators list, Fortune canvassed VCs, industry analysts, and our own formidable staff of AI experts to identify companies that are at the cutting edge. "One thing we know for sure," Clifford notes, "The work these companies are doing won't just shape the future of AI, it will shape the world we all live in." In the Fortune 50 AI list there are plenty of Davids, such as Adept, Runway, Pinecone, Exscientia, and ARC, to name a few. And no shortage of Goliaths, such as OpenAI, Anthropic, Google DeepMind, Meta, and Nvidia. What they have in common: "The work these companies are doing now will play a large part in determining not just how AI evolves, but how our world does," says Clifford. For a complete look at the Fortune 50 AI companies, go to fortune.com . Many on that list will be speaking at or attending the Fortune Brainstorm AI 2023 in San Francisco, December 11-12. This is the third year of Fortune's high-profile and news-making conference on AI. Curated by Fortune's editors, this year's annual conference for executives, academics, and policymakers will feature confirmed speakers including Vinod Khosla, founder and CEO of Khosla Ventures; Reid Hoffman, co-founder of Inflection AI and partner at Greylock Partners; Sal Khan, founder and CEO of Khan Academy; Clara Shih, CEO, Salesforce AI; Matthew Prince, CEO of Cloudflare; Jim Steyer, CEO of CommonSense Media; Paul Daugherty, chief technology and innovation officer, Accenture; Jim Cathey, chief commercial officer, Qualcomm; Lidia Fonseca, chief digital and technology officer, Pfizer; Sravana Karnati, chief technology officer, Walmart International; Anastasis Germanidis, co-founder and CTO, Runway; Mike Abbott, executive vice president, software, GM; Sissie Hsiao, general manager for Google Assistant and Bard, Google; Ali Ghodsi, CEO and founder of Databricks; Sayan Chakraborty, co-president of Workday, and more. This year's program is presented in association with Fortune Brainstorm AI conference founding partner Accenture, and will feature intimate one-on-one conversations, engaging panel discussions, and lively roundtable sessions–all designed to address how AI is changing the ways we do business. Fortune Brainstorm AI 2023 is also presented with partners AARP, Amgen, Check Point, Felicis, Salesforce, and Workday. For more information on Fortune Brainstorm AI 2023 and the complete agenda please go here . About Fortune Fortune upholds a legacy of award-winning writing and trusted reporting for executives who want to make business better. Independently owned, with a global perspective and digital agility, Fortune tells the stories of a new generation of innovators, builders, and risk takers. Online and in print, Fortune measures corporate performance through rigorous benchmarks, and holds companies accountable. Fortune creates communities by convening true thought leaders and iconoclasts – those who shape industry, commerce and society – through powerful and prestigious lists, events and conferences, such as the iconic Fortune 500, the CEO Initiative and Most Powerful Women. For more information, visit fortune.com . Contact:
Exscientia Frequently Asked Questions (FAQ)
When was Exscientia founded?
Exscientia was founded in 2012.
Where is Exscientia's headquarters?
Exscientia's headquarters is located at The Schrodinger Building, Oxford.
What is Exscientia's latest funding round?
Exscientia's latest funding round is IPO.
How much did Exscientia raise?
Exscientia raised a total of $673.7M.
Who are the investors of Exscientia?
Investors of Exscientia include Bill & Melinda Gates Foundation, GT Healthcare Capital Partners, Novo Holdings, Bristol Myers Squibb, SoftBank and 15 more.
Who are Exscientia's competitors?
Competitors of Exscientia include Aitia, Gero, MindRank, Causaly, BIOS Health and 7 more.
Loading...
Compare Exscientia to Competitors
Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Insilico Medicine operates as a clinical-stage biotechnology company operating in pharmaceutical research and development. It offers services that include novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis, enabled by advanced machine learning techniques. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Loading...